Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Despite its unparalleled merits for prostate cancer detection and staging, prostate-specific antigen (PSA) is not a marker for prostate cancer only, but also is expressed in benign conditions. For early detection, limitations of PSA are obvious. Its widespread use has led to an extensive amount of e...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Haese, A, Graefen, M, Huland, H, Lilja, H
Format:	Journal article
Język:	English
Wydane:	2004

Podobne zapisy

[Isoforms of free prostate-specific antigen]
od: Haese, A, i wsp.
Wydane: (2004)

Isoforms of free prostate-specific antigen
od: Haese, A, i wsp.
Wydane: (2004)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
od: Steuber, T, i wsp.
Wydane: (2002)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
od: Haese, A, i wsp.
Wydane: (2003)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
od: Haese, A, i wsp.
Wydane: (2003)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
od: Steuber, T, i wsp.
Wydane: (2005)

Prediction of tumor heterogeneity in localized prostate cancer.
od: Huland, H, i wsp.
Wydane: (2002)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
od: Botchorishvili, G, i wsp.
Wydane: (2009)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
od: Haese, A, i wsp.
Wydane: (2000)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
od: Steuber, T, i wsp.
Wydane: (2007)

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
od: Aalamian, M, i wsp.
Wydane: (2003)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
od: Steuber, T, i wsp.
Wydane: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
od: Lilja, H, i wsp.
Wydane: (2008)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
od: Haese, A, i wsp.
Wydane: (2003)

Biology of prostate-specific antigen
od: Lilja, H
Wydane: (2003)

Biology of prostate-specific antigen.
od: Lilja, H
Wydane: (2003)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
od: Haese, A, i wsp.
Wydane: (2005)

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.
od: Végvári, A, i wsp.
Wydane: (2010)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
od: Vickers, A, i wsp.
Wydane: (2011)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
od: Haese, A, i wsp.
Wydane: (2001)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
od: Bangma, C, i wsp.
Wydane: (2010)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
od: Vickers, A, i wsp.
Wydane: (2009)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
od: Denmeade, SR, i wsp.
Wydane: (2003)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
od: Denmeade, SR, i wsp.
Wydane: (2003)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
od: Lilja, H, i wsp.
Wydane: (2008)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
od: Aus, G, i wsp.
Wydane: (2004)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
od: Vickers, A, i wsp.
Wydane: (2010)

Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer
od: Azmi A Haroun, i wsp.
Wydane: (2011-01-01)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
od: Cao, Y, i wsp.
Wydane: (2002)

Prostatic specific antigen for prostate cancer detection
od: Lucas Nogueira, i wsp.
Wydane: (2009-10-01)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
od: Becker, C, i wsp.
Wydane: (2001)

Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
od: Jun Seok Kim, i wsp.
Wydane: (2015-04-01)

Prostate-Specific antigen: An overview and its current status in the diagnosis of prostate cancer
od: Siddalingeshwar Neeli, i wsp.
Wydane: (2021-01-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
od: Zh. R. Cherkasova, i wsp.
Wydane: (2023-03-01)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
od: Evans-Axelsson, S, i wsp.
Wydane: (2012)

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
od: Nurmikko, P, i wsp.
Wydane: (2002)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
od: Blijenberg, BG, i wsp.
Wydane: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
od: Becker, C, i wsp.
Wydane: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
od: Becker, C, i wsp.
Wydane: (2003)

Prostate-specific Antigen as a Predictor for the Diagnosis of Prostate Adenocarcinoma
od: Wilfredo Valiente Morejón, i wsp.
Wydane: (2015-11-01)